TGTX News & Events

TG Therapeutics announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous Briumvi, the company's anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis. Briumvi is currently approved in the United States and several ex-US territories as a one-hour intravenous infusion administered twice a year, following the starting dose, in adults with RMS.

In connection with the new facility, the Company's Board of Directors authorized an increase to its share repurchase program from $100 million to $300 million. As of March 18, 2026, the Company has repurchased approximately $38 million of common stock under the prior and existing share repurchase program at an average price of $28.98 per share.

TG Therapeutics entered into a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital. As part of the transaction, the Company will repay its outstanding $250 million senior secured credit facility, resulting in a net raise of $500 million in non-dilutive capital. The new facility also provides for up to an additional $250 million of incremental capital, for a total facility size of up to $1 billion, available at the mutual discretion of TG and Blue Owl.

TG Therapeutics announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating Briumvi in people with highly active relapsing forms of multiple sclerosis. The article, authored by Hans-Peter Hartung, MD, of Heinrich Heine University Dusseldorf and colleagues, was published in Neurology and Therapy. The analysis evaluated efficacy outcomes in participants with highly active disease at baseline, defined as greater than or equal to 2 relapses in the year prior and greater than or equal to 1 gadolinium-enhancing T1 lesion at baseline. Results demonstrated statistically significant reductions in relapse rates and MRI activity, as well as significantly higher rates of no evidence of disease activity, with Briumvi compared to teriflunomide.